Searched for
NOVARTIS LATEST NEWS
TrumpRx explained: How Trump’s new drug price deals with 9 pharma companies could save patients moneyTrumpRx: President Donald Trump has struck new deals with nine major drug companies. These agreements aim to reduce prescription drug price...- Novartis signs up to $5.2 billion heart drugs licensing deal with China's ArgoNovartis has entered into a licensing and options agreement with Argo Biopharmaceutical, valued at up to $5.2 billion. The deal encompasses...
- MNC pharma companies: Time to take a re-look? 8 pharma stocks, 5 with an upside of up to 34%Some time back an MNC pharma firm announced the divestment of one of its businesses in India. Another sold one of its plants. Now, with the...
- MNC pharma: Time to re-look at them without bias? 8 MNC pharma stocks, 5 with an upside potential of 15 to 52%While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old theory that h...
- MNC pharma: Time to relook at them? 8 pharma stocks, 4 with an upside potential of between 16 and 47%In the past four years, several MNC pharma companies announced the sale of a part of their businesses in India. Some of this was part of gl...
- Indian companies have made a comeback. Will MNCs be able to do it ? 7 MNC pharma stocks with upside potential of up to 21%While they still trade at premium valuations, they have not created wealth for shareholders. The fact is an age-old theory that just having...
- Will the wave of restructuring help? 7 MNC pharma stocks with upside potential of up to 14%In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of thes...
- Powell just one global central banker under political pressureThe independence that monetary policy makers have traditionally enjoyed is under threat.
- FDI green light to spark M&As in pharma sectorUntil now to buy into an Indian enterprise, multinational drug companies needed an approval from FIPB under department of industrial policy...
- Poor growth of anti-infective segment remains a concern for pharmaceutical sectorThe latest growth numbers released for the month of February 2013 do not hold good news for the Indian pharma industry.
- Natco’s compulsory licence for selling generic copies of Bayer’s cancer drug Nexavar upheld by IpabThe Indian patents appeals board had last year dismissed Bayer’s petition seeking a stay on the “compulsory licence” issued to Natco.
- Of patents and pre-grant oppositionsOn January 25 this year, the patent office in Chennai rejected a patent application by pharma MNC Novartis for its anti-cancer drug Glivec ...
Load More
